CDAK Codiak BioSciences Inc.

Biotech Analyst Ratings

Latest News

1. 17 May 2022 Codiak Presents New Preclinical Data at ASGCT 2022 on Exosome-Based Strategy to Enhance AAV Gene Therapy

   CAMBRIDGE, Mass., May 17, 2022 (GLOBE NEWSWIRE) -- Codiak BioSciences, Inc. (NASDAQ:CDAK), a clinical-stage biopharmaceutical company pioneering the development of exosome-based therapeutics as a new class of medicines, today announced new preclinical data on the Company's engEx-AAV™ discovery program, a novel strategy that aims to leverage exosomes to improve adeno-associated virus (AAV) vector gene therapy. The data, which are being presented today at the 25^th Annual Meeting of the American Society of Gene and Cell Therapy (ASGCT), demonstrate that exosome engineering generates significant increases in AAV yield compared to unmodified exosomes, while retaining the functionality to transduce cells with AAV and resist neutralizing antibodies…

   View Full Article
2. 05 May 2022 Codiak BioSciences Reports First Quarter 2022 Financial Results and Operational Progress

   – Codiak to provide data from ongoing exoSTING™ and exoIL-12™ clinical trials in late 1H 2022 –

   – Anticipate first patients dosed in exoASO™-STAT6 Phase 1 clinical trial in 1H 2022 –

   – Data from preclinical engEx-AAV™ program to be presented at ASGCT 2022 showing potential applications for engineered exosomes in gene delivery –

   CAMBRIDGE, Mass., May 05, 2022 (GLOBE NEWSWIRE) -- Codiak BioSciences, Inc. (NASDAQ:CDAK), a clinical-stage biopharmaceutical company focused on pioneering the development of exosome-based therapeutics as a new class of medicines, today reported first quarter 2022 financial results and operational progress.

   "We are making exciting progress with our clinical and preclinical programs, which continue to generate further…

   View Full Article
3. 02 May 2022 Codiak Appoints David Mauro, M.D., Ph.D., as Chief Medical Officer

   CAMBRIDGE, Mass., May 02, 2022 (GLOBE NEWSWIRE) -- Codiak BioSciences, Inc. (NASDAQ:CDAK), a clinical-stage biopharmaceutical company pioneering the development of exosome-based therapeutics as a new class of medicines, today announced the appointment of David Mauro, M.D., Ph.D., a veteran oncology and immunotherapy drug developer, as Chief Medical Officer. Dr. Mauro will provide leadership and expertise for Codiak's pipeline of clinical development programs through early-stage trials to global regulatory submissions and joins the company's Executive Leadership Team reporting to Douglas E. Williams, Ph.D., President and CEO.
   

   "We have been fortunate to work with David since late last year in an advisory capacity and are delighted to welcome…

   View Full Article
4. 20 April 2022 Codiak Presents New Preclinical Data Supporting Development of a Broadly Protective Pan Beta-Coronavirus Vaccine

   – Engineered exosome vaccine construct generated durable, comprehensive immunity in vivo –
   

   CAMBRIDGE, Mass., April 20, 2022 (GLOBE NEWSWIRE) -- Codiak BioSciences, Inc. (NASDAQ:CDAK), a clinical-stage biopharmaceutical company focused on pioneering the development of exosome-based candidates as a new class of medicines, today announced new preclinical data from its pan beta-coronavirus vaccine program, which aims to protect against all SARS-CoV-2 variants of concern and potential future strains belonging to the beta-coronavirus family. The data, which are being presented today at the World Vaccine Congress 2022 in Washington, D.C., demonstrate the potential for a novel engineered exosome-based vaccine candidate derived from Codiak's exoVACC™…

   View Full Article
5. 08 April 2022 Codiak's exoASO™-C/EBPβ Demonstrates Significant Systemic Anti-Tumor Activity via Targeting Immune-Suppressive Myeloid Cells

   – New preclinical data presented at AACR Annual Meeting 2022 –

   – Intravenous exosome candidate engineered for tropism precisely targets transcription factors in myeloid cell subpopulations –

   – Precision medicine approach enables potent single-agent activity in models of widely disseminated tumors –

   CAMBRIDGE, Mass., April 08, 2022 (GLOBE NEWSWIRE) -- Codiak BioSciences, Inc. (NASDAQ:CDAK), a clinical-stage biopharmaceutical company focused on pioneering the development of exosome-based therapeutics as a new class of medicines, today announced new preclinical data on the Company's engineered exosome precision medicine candidate, exoASO-C/EBPβ. The data, which will be presented at the American Association for Cancer Research (AACR…

   View Full Article